Lifeboat Foundation

The recipient of the world’s first Neuralink brain-chip transplant is able to control a computer mouse by thinking, the tech startup’s founder Elon Musk announced this week.

“Progress is good, and the patient seems to have made a full recovery, with no ill effects that we are aware of,” Reuters reported that Musk said in an X Spaces event on Monday. “Patient is able to move a mouse around the screen by just thinking.”

Musk added that Neuralink was trying to get the patient to click the mouse as much as possible, Reuters reported.

The billionaire’s brain device company is currently recruiting patients in the US, UK and Canada.

Tissues take shape during development through a series of morphogenetic movements guided by local cell-scale forces. While current in vitro approaches subjecting tissues to homogenous stresses, it is currently no possible to recapitulate highly local spatially varying forces. Here we develop a method for local actuation of organoids using embedded magnetic nanoparticles. Sequential aggregation of magnetically labelled human pluripotent stem cells followed by actuation by a magnetic field produces localized magnetic clusters within the organoid. These clusters impose local mechanical forces on the surrounding tissue in response to applied global magnetic fields. We show that precise, spatially defined actuation provides short-term mechanical tissue perturbations as well as long-term cytoskeleton remodeling. We demonstrate that local magnetically-driven actuation guides asymmetric growth and proliferation, leading to enhanced patterning in human neural organoids. We show that this approach is applicable to other model systems by observing polarized patterning in paraxial mesoderm organoids upon local magnetic actuation. This versatile approach allows for local, controllable mechanical actuation in multicellular constructs, and is widely applicable to interrogate the role of local mechanotransduction in developmental and disease model systems.

The authors have declared no competing interest.

Sometimes there are slightly different versions, or sequences of genes. There are several versions of the apolipoprotein E (APOE) gene, for example. One of them, called APOE4, has been linked to a much higher risk of developing Alzheimer’s disease, and carriers often have worse forms of the disease compared to carriers of other forms like APOE3. There are immune cells in the brain called microglia that help protect the brain from damage and harm. But when APOE4 is expressed, microglia seem to start to cause inflammation, and misfolded proteins to form in the brain, which can lead to serious problems. The findings have been reported in Cell Stem Cell.

In this work, the researchers developed a mouse model that could generate the human APOE4 protein in their brains. Next, the investigators eliminated microglia from these mouse brains. The formation of two misfolded proteins that are hallmarks of Alzheimer’s diseases: amyloid and tau, was halted.

Summary: Autism-linked SHANK3 gene mutations disrupt not only neurons but also oligodendrocytes, essential for producing myelin, which insulates nerve fibers. This damage reduces brain signal efficiency and impairs behavior.

Using gene therapy, researchers successfully repaired these cells in a mouse model, restoring their function and myelin production. They validated their findings with human-derived stem cells, confirming similar impairments and repair mechanisms.

This discovery highlights a significant role for oligodendrocytes in autism and opens the door for innovative treatments targeting myelin dysfunction. The study underscores both the biological complexity of autism and the promise of genetic therapies for intervention.

Can therapy rewire the brain? For individuals struggling with both depression and obesity, a new Stanford Medicine study says yes—when the therapy is the right fit. Researchers found that cognitive behavioral therapy focused on problem-solving reduced depression symptoms in a third of participants and altered their brain activity in ways that could predict longer-term benefits. The findings have been published in Science Translational Medicine.

Depression affects millions of people worldwide and becomes particularly challenging to treat when paired with obesity, a condition that complicates recovery and worsens outcomes. Previous research has suggested that brain regions associated with cognitive control—areas responsible for regulating emotions and behaviors—might influence how individuals respond to therapy.

This study aimed to determine whether a therapy specifically designed to engage these brain circuits could lead to sustained improvements in depression symptoms, particularly in individuals with comorbid depression and obesity. The researchers also investigated whether early changes in brain activity could predict long-term therapeutic success, paving the way for more personalized treatment strategies.

It’s been more than three decades, but still there are only two treatments for a stroke: either rapid use of a clot-busting medication called tPA or surgical removal of a clot from the brain with mechanical thrombectomy. However, only 5% to 13% percent of stroke cases are actually eligible for these interventions.

“We need to be persistent with our research to find a new therapy for stroke,” says Rajkumar Verma, M.Pharm., Ph.D., assistant professor, Department of Neuroscience at UConn School of Medicine working in cross-campus collaboration with Professor Raman Bahal Ph.D. of the Department of Pharmaceutical Sciences in the UConn School of Pharmacy. “Stroke research is hard and challenging to do. But without trying we won’t make progress. We need to keep trying. UConn is determined to keep trying.”

In addition to being life-threatening, stroke is the major cause of long-term disability worldwide.

Injectable magnetoelectric nanodiscs may activate neurons in localized brain regions when stimulated by a weak external magnetic field, say MIT scientists.

Cognitive neuroscientists at Trinity College Dublin have published new research describing a brand new approach to making habit change achievable and lasting.

This innovative framework has the potential to significantly improve approaches to personal development, as well as the clinical treatment of compulsive disorders (for example obsessive compulsive disorder, addiction, and eating disorders).

The research was led by Dr. Eike Buabang, Postdoctoral Research Fellow in the lab of Professor Claire Gillan in the School of Psychology, has been published as a paper titled “Leveraging cognitive neuroscience for making and breaking real-world habits” in the journal Trends in Cognitive Sciences.